More on TFX
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $136.58 |
|
|||
| Open | $136.45 | ||||
| 52 Wk High | $188.79 | ||||
| 52 Wk Low | $125.28 | ||||
| Day High | $137.55 | ||||
| Day Low | $135.83 | ||||
| P/E | 39.43 | ||||
| EPS | $3.46 | ||||
| Volume | 25,959 | ||||
- FDA grants Teleflex breakthrough device status for coronary scaffold
- Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold
- Teleflex Announces Third Quarter 2026 Earnings Conference Call Information
- Teleflex (TFX) PT Lowered to $142 at Truist Securities
- Teleflex completes enrollment in BIOMAG-LL magnesium scaffold study
- Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
- Teleflex study links catheter technology to 70% lower CLABSI risk
- Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
- Nyxoah Appoints Liam Kelly as Chief Executive Officer
- BofA Securities Upgrades Teleflex (TFX) to Buy
Entities mentioned with TFX
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Show More...
